This explorer™ G3 integrated HTS workstation is a fully automated,high-throughput system that incorporates AlphaLISA® technology, a novel, homogeneous, bead-based immunoassay to replace traditional ELISA assays in drug discovery, diagnostics and basic research.
false falseFor research use only. Not for use in diagnostic procedures.
Configuration Requirements:
PerkinElmer’s AlphaLISA® technology is a novel, homogeneous, bead-based assay technology which can be used to replace traditional ELISA assays in drug discovery, diagnostics, and basic research. Because AlphaLISA assays are homogeneous, they can easily be automated. As an added value, AlphaLISA technology has been demonstrated to successfully work in high density formats (384-and 1536-well plates) enabling researchers to run high numbers of samples in small sample volumes.
Utilizing our proven explorer™ G3 integrated HTS workstation, we have designed a true single supplier, fully automated high-throughput AlphaLISA screening platform for use by a major pharmaceutical company. Sample transfer and standard addition are carried out by a PerkinElmer JANUS® automated liquid handling platform fitted with 96-tip pipetting head. Antibody solution and AlphaScreen® beads are dispensed by 2x PerkinElmer FlexDrop® IV dispensers. The two FlexDrop IV dispensers provide a total of eight independent dispense channels enabling the operator to run plates using different protocols within one run. Following incubation, plates are read on PerkinElmer’s EnVision® multimode reader.
In a recent study, a team of international researchers used genomic data from modern human populations to better understand how humans have adapted to historical coronavirus outbreaks. They found evidence of an ancient coronavirus outbreak in East Asia over 20,000 years ago. Read on to see how these findings could help countries rethink the way they prepare for public health crises of the future.
